High Frequencies of Virus-Specific CD8(+) T-Cell Precursors

Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Journal of Virology (Impact Factor: 4.65). 10/2009; 83(24):12907-16. DOI: 10.1128/JVI.01722-09
Source: PubMed

ABSTRACT A productive CD8(+) T-cell response to a viral infection requires rapid division and proliferation of virus-specific CD8(+) T cells. Tetramer-based enrichment assays have recently given estimates of the numbers of peptide-major histocompatibility complex-specific CD8(+) T cells in naïve mice, but precursor frequencies for entire viruses have been examined only by using in vitro limiting-dilution assays (LDAs). To examine CD8(+) T-cell precursor frequencies for whole viruses, we developed an in vivo LDA and found frequencies of naïve CD8(+) T-cell precursors of 1 in 1,444 for vaccinia virus (VV) ( approximately 13,850 VV-specific CD8(+) T cells per mouse) and 1 in 2,958 for lymphocytic choriomeningitis virus (LCMV) ( approximately 6,761 LCMV-specific CD8(+) T cells per mouse) in C57BL/6J mice. In mice immune to VV, the number of VV-specific precursors, not surprisingly, dramatically increased to 1 in 13 ( approximately 1,538,462 VV-specific CD8(+) T cells per mouse), consistent with estimates of VV-specific memory T cells. In contrast, precursor numbers for LCMV did not increase in VV-immune mice (1 in 4,562, with approximately 4,384 LCMV-specific CD8(+) T cells per VV-immune mouse). Using H-2D(b)-restricted LCMV GP33-specific P14-transgenic T cells, we found that, after donor T-cell take was accounted for, approximately every T cell transferred underwent a full proliferative expansion in response to LCMV infection. This high efficiency was also seen with memory populations, suggesting that most antigen-specific T cells will proliferate extensively at a limiting dilution in response to infections. These results show that frequencies of naïve and memory CD8(+) T cell precursors for whole viruses can be remarkably high.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Our previous in vivo studies show that both the amount of Ag and the number of available naive CD4 T cells affect the Th1/Th2 phenotype of the effector CD4 T cells generated. We examined how the number of OVA-specific CD4 TCR transgenic T cells affects the Th1/Th2 phenotype of anti-SRBC CD4 T cells generated in vivo upon immunization with different amounts of OVA-SRBC. Our observations show that a greater number of Ag-dependent CD4 T cell interactions are required to generate Th2 than Th1 cells. We established an in vitro system that recapitulates our main in vivo findings to more readily analyze the underlying mechanism. The in vitro generation of Th2 cells depends, as in vivo, upon both the number of responding CD4 T cells and the amount of Ag. We demonstrate, using agonostic/antagonistic Abs to various costimulatory molecules or their receptors, that the greater number of CD4 T cell interactions, required to generate Th2 over Th1 cells, does not involve CD40, OX40, or ICOS costimulation, but does involve B7/CD28 interactions. A comparison of the level of expression of B7 molecules by APC and CD4 T cells, under different conditions resulting in the substantial generation of Th1 and Th2 cells, leads us to propose that the critical CD28/B7 interactions, required to generate Th2 cells, may directly occur between CD4 T cells engaged with the same B cell acting as an APC.
    The Journal of Immunology 04/2014; 192(11). DOI:10.4049/jimmunol.1301691 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Protection from lethality by post-challenge administration of brincidofovir (BCV, CMX001) was studied in normal and immune-deficient (nu-/nu-) BALB/c mice infected with vaccinia virus (VACV). Whole body bioluminescence imaging was used to record total fluxes in the nasal cavity, lungs, spleen, and liver and to enumerate pox lesions on tails of mice infected via the intranasal route with 10(5) pfu of recombinant IHD-J-Luc VACV expressing luciferase. Areas Under the flux Curve (AUC) were calculated for individual mice to assess viral loads. A 3 dose regimen of 20 mg/kg BCV administered every 48 hours starting either on Day 1 or Day 2 post-challenge protected 100% of mice. Initiating BCV treatment earlier was more efficient in reducing viral loads and in protecting from pox lesion development. All BCV-treated mice that survived challenge were also protected from re-challenge with IHD-J-Luc or WRvFire VACV without additional treatment. In immune-deficient mice, BCV protected animals from lethality and reduced viral loads while on drug. Viral recrudescence occurred within 4-9 days and mice succumbed ∼10-20 days after treatment termination. Nude mice reconstituted with 10(5) T cells prior to challenge with 10(4) pfu of IHD-J-Luc and treated with BCV post-challenge survived the infection, cleared the virus from all organs, and survived re-challenge with 10(5) pfu of IHD-J-Luc VACV without additional BCV treatment. Together, these data suggest that BCV protects immune competent and partially T-cell reconstituted immune-deficient mice from lethality, reduces viral dissemination in organs, prevents pox lesion development, and permits generation of VACV-specific memory. Mass vaccination is the primary element of the public health response to a smallpox outbreak. In addition to vaccination, however, antiviral drugs are required for individuals with uncertain exposure status to smallpox, or for whom vaccination is contraindicated. Whole body bioluminescence imaging was used to study the effect of brincidofovir (BCV) in normal and immune-deficient (nu-/nu-) mice infected with vaccinia virus, a model of smallpox. Post-challenge administration of 20 mg/kg BCV rescued normal and immune-deficient mice partially reconstituted with T cells from lethality and significantly reduced viral loads in organs. All BCV-treated mice that survived infection were protected from re-challenge without additional treatment. In immune-deficient mice, BCV extended survival. The data show that BCV controls viral replication at the site of challenge and reduces viral dissemination to internal organs thus providing a shield for the developing adaptive immunity that clears the host of virus and builds virus-specific immunological memory. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Journal of Virology 01/2015; DOI:10.1128/JVI.03340-14 · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundIn response to antigen naive CD8+, T cells differentiate into effector cells, which express Natural killer (NK) receptors, lose CD28 expression, and die by apoptosis. However, in smaller quantities, the cells are retained for subsequent exposure to the same antigen. Knowledge is limited regarding whether the percentages of CD28-, Effector memory (EMRAnull/dim), and the CD16+/CD56 + CD8+ T cells of women with low-grade cervical lesions are altered at a systemic level.MethodsWe enrolled in this study women controls and women with Human papilloma virus infection (HPV-I) without associated cellular neoplastic changes and with Cervical Intraepithelial Neoplastic-I (CIN-I). Flow cytometry (FC) was performed for measurement of CD28-, memory subset, and NK-like CD8 + T cells, and IL-17, IFN-gamma, Tumor necrosis factor (TNF)-alpha, Interleukin (IL)-10, IL-6, IL-4, and IL-2. Finally, we genotyped the HPV.ResultsThe CIN-I group increased the CD8 + CD28− and CD16+/56+ T cell percentage compared with that of HPV-I and controls (p <0.01), and CD8 + CCR7-CD45RAnull/dim (EMRAnull/dim) T cells were also increased in the CIN-I group compared with the controls (p <0.01). These two study groups were HPV- genotyped; 49% were HPV18+, and we did not observe differences in cytokine levels among all groups.ConclusionsIncreased levels of CD28-, EMRAnull/dim, and CD16+/CD56 + CD8+ T cells of peripheral blood in women with CIN-I may be associated with persistent HPV infection and could exert an influence on progression to cervical cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12935-014-0097-5) contains supplementary material, which is available to authorized users.
    Cancer Cell International 09/2014; 14(1):97. DOI:10.1186/s12935-014-0097-5 · 1.99 Impact Factor


Available from